BRILINTA 90 MG
TICAGRELOR : 90 MG · DIN 02368544 · ASTRAZENECA CANADA INC
Health Canada status: MARKETED
What is BRILINTA?
BRILINTA 90 MG contains TICAGRELOR : 90 MG. It is listed in the Health Canada Drug Product Database under DIN 02368544, held by ASTRAZENECA CANADA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 01-Jun-2011. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is BRILINTA used for?
Secondary prevention of atherothrombotic events in ACS, history of MI (≥1 year), or CAD with Type 2 DM and history of PCI. Co-administered with low-dose ASA.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02368544 |
|---|---|
| Brand name | BRILINTA |
| Generic / active ingredient | TICAGRELOR : 90 MG |
| Manufacturer | ASTRAZENECA CANADA INC |
| Strength | 90 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | B01AC24 TICAGRELOR |
| AHFS class | 20:12.18 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 01-Jun-2011 |
| Original market date | 2011-06-01 00:00:00 |
How is it administered?
ACS: 180 mg loading dose, then 90 mg bid. History of MI/CAD with Type 2 DM: 60 mg bid. Administer with low-dose ASA (75-150 mg daily). Can be taken with or without food.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store at 15-30°C (implied by standard Canadian monograph storage, though specific text was truncated, the "Storage, Stability" section is listed in TOC).
How is it supplied?
90 mg: Blister packs of 60, HDPE bottles of 60 (institutional). 60 mg: Blister packs of 60, HDPE bottles of 60.
Contraindications
Hypersensitivity; active pathological bleeding (e.g., peptic ulcer, intracranial hemorrhage); history of intracranial hemorrhage; moderate to severe hepatic impairment; use with strong CYP3A4 inhibitors.
Warnings and precautions
Increased bleeding risk; risk of bradyarrhythmia (ventricular pauses); dyspnea; uric acid increase (gout); risk of cardiac events upon premature discontinuation.
What can be used instead?
Other Canadian products sharing ATC code B01AC24 TICAGRELOR. 12 of 14 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AG-TICAGRELOR | 60 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02537184 |
| AG-TICAGRELOR | 90 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02537192 |
| APO-TICAGRELOR | 60 MG | TABLET | APOTEX INC | MARKETED | DIN 02482622 |
| APO-TICAGRELOR | 90 MG | TABLET | APOTEX INC | MARKETED | DIN 02482630 |
| BRILINTA | 60 MG | TABLET | ASTRAZENECA CANADA INC | MARKETED | DIN 02455005 |
| JAMP TICAGRELOR | 60 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02531798 |
| JAMP TICAGRELOR | 90 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02531801 |
| M-TICAGRELOR | 60 MG | TABLET | MANTRA PHARMA INC | MARKETED | DIN 02529750 |
| M-TICAGRELOR | 90 MG | TABLET | MANTRA PHARMA INC | MARKETED | DIN 02529769 |
| TARO-TICAGRELOR | 60 MG | TABLET | TARO PHARMACEUTICALS INC | MARKETED | DIN 02492571 |
Who else supplies TICAGRELOR worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. TICAGRELOR appears in 424 registered pack listings across 15 markets, published on 12 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.